RO7300490
- Generic Name
- RO7300490
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
RO7300490 is an investigational Fibroblast Activation Protein-α (FAP) targeted CD40 agonist. RO7300490 is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT04857138
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇬🇧Western General Hospital; Edinburgh Cancer Center, Edinburgh, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath